BECN1 and gastric cancer: Patients with Beclin 1 low expression gastric cancer showed significantly shorter 5-year overall survival rates (OS, p = .011; Fig. 3) and disease free survival (DFS, p = .010; Fig. 4) than those with Beclin 1 high expression ones.